Drugmaker BioLineRx Beats Investor Suit Over Cash Shortfall

By Katryna Perera · July 16, 2024, 7:00 PM EDT

Israeli biotech company BioLineRx has, for now, beaten a proposed class action over claims that it misled investors on its capital shortfall, which caused a major decline in its share price,...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

IN RE BIOLINERX LTD. SECURITIES LITIGATION

Case Number

Court

New Jersey

Nature of Suit

Securities/Commodities

Date Filed

January 05, 2023

Recent Articles By Katryna

July 15, 2024
CVS Hit With Investor Suit Over Benefits Unit's Losses
July 01, 2024
Delta Dental Wants Antitrust Claims Standard Decided Now
June 06, 2024
White Collar Boutique Sued By Ex-Client Over Representation
June 04, 2024
Biotech RenovaCare Can't Beat Investors' Stock Promo Suit
June 03, 2024
Humana Hit With Investor Suit Over Post-COVID Costs
May 30, 2024
Veradigm Execs Sued Over Company's Nasdaq Delisting
May 20, 2024
iRhythm Brass Face Suit Over FDA's Heart Monitor Inquiry
May 02, 2024
Masimo Hit With Derivative Suit Over Audio Co. Acquisition
May 01, 2024
Insulin Pump Maker Wins Toss of Investor Suit For Now
April 30, 2024
Vaxart Investors Want Sanctions Over Deleted Texts